Percentage of dealth is not significant at all. But I think AFFY took an extreme measure which is good on PR standpoint. It was good for me nonetheless as short terms it allowed me to buy shares on the cheap: 50000 shares at 1.14. Long terms AFFY will be praised by the medical and patients that it is indeed a safe drug when it is reintroduced by my rough estimate whcih should be by the end of the year. Can you guess the share price then?
What you don't understand is:
-the drug will get back to market. 100% guarantee, because it works and well...... minimum % risks
-problem will be marketing it after the bad advertising it's got
That's why it will be sold/take over (positive from this point PPS)..... or AFFY will go BK if they go for a new trial a can't find new investors.
In case they do a new safety trial and find a new investor, at this 1/2$ level there will be a huge diluition.... at least 50 Mil$..... that is more than 40/50% diluition.
The drug is everything but dead. It will sell and big.... but in other's hands (bankrupt and sellof or buyout).
Forget the chance of a return to market with a skin-stripe test.
This is only for saying: *******DON'T RISK TOO MUCH********.
1- BK... (40% chance)
2- Buyout (what PPS and when?).... (40% chance)
3- AFFY fixes all problems with a new safety trial..... strong diluition.....back to market in 2 years... (15% chance)
4- back to market with minimum expenses and less than 6 months...(5% chance)
Tomorrow, I'm buying back 2k shares...... total risk.for #1